This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Oct 7;390(10103):1626-1628.

doi: 10.1016/S0140-6736(17)31965-7. Epub 2017 Jul 27.

Bevacizumab in cervical cancer: a step forward for survival

Susana Banerjee¹

Affiliations

Affiliation

¹ Gynaecology Unit, Royal Marsden National Health Service Foundation Trust and Division of Clinical Studies, Institute of Cancer Research, Royal Marsden Hospital, London SW3 6JJ, UK. Electronic address: susana.banerjee@rmh.nhs.uk.

PMID: 28756904
DOI: 10.1016/S0140-6736(17)31965-7

Comment

Bevacizumab in cervical cancer: a step forward for survival

Susana Banerjee. Lancet. 2017.

. 2017 Oct 7;390(10103):1626-1628.

doi: 10.1016/S0140-6736(17)31965-7. Epub 2017 Jul 27.

Author

Susana Banerjee¹

Affiliation

¹ Gynaecology Unit, Royal Marsden National Health Service Foundation Trust and Division of Clinical Studies, Institute of Cancer Research, Royal Marsden Hospital, London SW3 6JJ, UK. Electronic address: susana.banerjee@rmh.nhs.uk.

PMID: 28756904
DOI: 10.1016/S0140-6736(17)31965-7

No abstract available

PubMed Disclaimer

Comment on

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Tewari KS, et al. Lancet. 2017 Oct 7;390(10103):1654-1663. doi: 10.1016/S0140-6736(17)31607-0. Epub 2017 Jul 27. Lancet. 2017. PMID: 28756902 Free PMC article. Clinical Trial.

Similar articles

Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
Krill LS, Tewari KS. Krill LS, et al. Expert Opin Pharmacother. 2015 Apr;16(5):675-83. doi: 10.1517/14656566.2015.1010511. Epub 2015 Feb 3. Expert Opin Pharmacother. 2015. PMID: 25643984 Review.
A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.
Minion LE, Bai J, Monk BJ, Robin Keller L, Ramez EN, Forde GK, Chan JK, Tewari KS. Minion LE, et al. Gynecol Oncol. 2015 Jun;137(3):490-6. doi: 10.1016/j.ygyno.2015.02.027. Epub 2015 Mar 10. Gynecol Oncol. 2015. PMID: 25766118
Bevacizumab treatment for solid tumors: boon or bust?
Hayes DF. Hayes DF. JAMA. 2011 Feb 2;305(5):506-8. doi: 10.1001/jama.2011.57. JAMA. 2011. PMID: 21285431 No abstract available.
Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T, Lindley C. Shih T, et al. Clin Ther. 2006 Nov;28(11):1779-802. doi: 10.1016/j.clinthera.2006.11.015. Clin Ther. 2006. PMID: 17212999 Review.
Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer.
Tewari KS, Monk BJ. Tewari KS, et al. Clin Adv Hematol Oncol. 2014 Nov;12(11):737-48. Clin Adv Hematol Oncol. 2014. PMID: 25674713 Review.

See all similar articles

Cited by

SQLE-a promising prognostic biomarker in cervical cancer: implications for tumor malignant behavior, cholesterol synthesis, epithelial-mesenchymal transition, and immune infiltration.
Zhao YC, Li YF, Qiu L, Jin SZ, Shen YN, Zhang CH, Cui J, Wang TJ. Zhao YC, et al. BMC Cancer. 2024 Sep 11;24(1):1133. doi: 10.1186/s12885-024-12897-0. BMC Cancer. 2024. PMID: 39261819 Free PMC article.
A panel of seven immune-related genes can serve as a good predictive biomarker for cervical squamous cell carcinoma.
Dai J, Pan Y, Chen Y, Yao S. Dai J, et al. Front Genet. 2022 Nov 2;13:1024508. doi: 10.3389/fgene.2022.1024508. eCollection 2022. Front Genet. 2022. PMID: 36406134 Free PMC article.
Prediction of recurrence-related factors for patients with early-stage cervical cancer following radical hysterectomy and adjuvant radiotherapy.
Ma GF, Lin GL, Wang ST, Huang YY, Xiao CL, Sun J, Shi TY, Xiang LB. Ma GF, et al. BMC Womens Health. 2024 Jan 31;24(1):81. doi: 10.1186/s12905-023-02853-8. BMC Womens Health. 2024. PMID: 38297248 Free PMC article.
Parents' attitudes, beliefs and uptake of the school-based human papillomavirus (HPV) vaccination program in Jakarta, Indonesia - A quantitative study.
Wijayanti KE, Schütze H, MacPhail C. Wijayanti KE, et al. Prev Med Rep. 2021 Nov 27;24:101651. doi: 10.1016/j.pmedr.2021.101651. eCollection 2021 Dec. Prev Med Rep. 2021. PMID: 34976699 Free PMC article.
Effect of Number of Retrieved Lymph Nodes on Prognosis in FIGO Stage IA1-IIA2 Cervical Cancer Patients Treated With Primary Radical Surgery.
Jiang S, Jiang P, Jiang T, Tu Y, Zhang J, Li N, Kong W, Huang Y, Yuan R. Jiang S, et al. Clin Med Insights Oncol. 2022 Sep 30;16:11795549221127161. doi: 10.1177/11795549221127161. eCollection 2022. Clin Med Insights Oncol. 2022. PMID: 36199803 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information